Glucagon‐like peptide‐1 receptor agonist use is associated with lower serum periostin.

Serum periostin is lower in asthmatics with T2DM using GLP-1RAs compared to alternative diabetes therapies. Prior studies identifying candidate biomarkers of GLP-1RA use critically lacked inclusion of patients with asthma.[[4]] Increasing data support periostin as a potential biomarker of GLP-1RA use. In conclusion, GLP-1RA use may attenuate the increased risk for poor asthma outcomes in patients with metabolic dysregulation and obesity by impacting pathways relevant to airway inflammation in humans. Consistent with prior asthma literature, patients with comorbid asthma (Biobank cohort) had higher mean levels of periostin than the non-asthma patients (RCT cohort). [Extracted from the article]